CYCC — Cyclacel Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $2.32m
- -$1.06m
- $0.42m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K/A | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 11.9 | 33.4 | 36.6 | 18.3 | 3.38 |
Net Total Receivables | 1.33 | 1.31 | 3.73 | 4.66 | 2.93 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 14 | 35.5 | 40.9 | 24.4 | 7.44 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.29 | 1.33 | 0.094 | 0.174 | 0.102 |
Other Long Term Assets | |||||
Total Assets | 15.3 | 36.8 | 42.6 | 28.1 | 8.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.42 | 2.49 | 5.29 | 7.51 | 8.16 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.61 | 3.54 | 5.32 | 7.62 | 8.2 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 11.7 | 33.3 | 37.3 | 20.4 | 0.607 |
Total Liabilities & Shareholders' Equity | 15.3 | 36.8 | 42.6 | 28.1 | 8.8 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |